Track topics on Twitter Track topics that are important to you
Nemaura Medical (NASDAQ:NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today published clinical data from its recently completed study intended to support a De Novo submission to the U.S Food & Drug Administration (“FDA”) for approval of its … Continued
The post Nemaura Publishes Positive Data from SugarBEAT FDA Clinical Trial appeared first on Investing News Network.
Original Article: Nemaura Publishes Positive Data from SugarBEAT FDA Clinical TrialNEXT ARTICLE
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...